- Home
- CHPG vs CALC Comparison
CHPG vs CALC Comparison
Compare CHPG & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHPG | CALC |
|---|---|---|
| Founded | 2024 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.3M | 88.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CHPG | CALC |
|---|---|---|
| Price | $10.29 | $5.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 2.9K | ★ 87.0K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $264.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $1.42 |
| 52 Week High | $10.28 | $7.20 |
Technical Indicators
Market Signals| Indicator | CHPG | CALC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.14 |
| Support Level | N/A | $5.04 |
| Resistance Level | N/A | $5.95 |
| Average True Range (ATR) | 0.00 | 0.67 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 0.00 | 17.82 |
Price Performance
Historical ComparisonAbout CHPG ChampionsGate Acquisition Corporation Class A Ordinary Share
Championsgate Acquisition Corp is a blank check company.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.